Vistagen Therapeutics Inc (NASDAQ:VTGN) reported the U.S. Patent and Trademark Office has issued U.S. Patent related to certain processes of production for AV-101, which is company’s major CNS product candidate. Shawn Singh, the CEO, expressed that issuance of this U.S. patent advances their intellectual property plan for AV-101 at this notable period in its clinical advancement. This issued U.S. patent, together with the potential release of more AV-101 patent applications presently under review globally, offers VistaGen with increased intellectual property protection for AV-101 and improves its commercial potential.
VistaGen is a clinical-stage biopharmaceutical firm focused on advancing new generation drugs for depression and other CNS ailments. Its key CNS product candidate named AV-101 is in Phase II development, preliminary as a new-gen oral antidepressant medication candidate for major depressive disorder.
Its mechanism of action is basically different from all FDA-permitted atypical antipsychotics and antidepressants used adjunctively to cure MDD, with potential to lead a paradigm shift towards an advanced generation of faster-acting and safer antidepressants. AV-101 is presently being assessed by the National Institute of Mental Health in a small Phase II monotherapy trial in MDD being fully supported by the NIMH and performed by Dr. Carlos Zarate Jr.
VistaGen is intending to release a 180-patient Phase II trial of AV-101 as an adjunctive therapy for people with MDD with an insufficient response to standard, FDA-permitted antidepressants, with Dr. Maurizio Fava as Principal Investigator.
The lead drug candidate, AV-101 may also showcase the potential to cure neurodegenerative diseases and multiple CNS disorders in addition to Major Depressive Disorder, including epilepsy, neuropathic pain, Parkinson’s disease levodopa-resultant dyskinesia, Huntington’s disease and other ailments.
In the last trading session, the stock price of VistaGen jumped more than 95% to close the day at $1.80. The gains came at a share volume of 40.69 million compared to average share volume of 598,639.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: